Announced
Completed
Synopsis
Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, completed the acquisition of Rahko, a quantum machine learning company. Financial terms were not disclosed. "Rahko's powerful platform will play a direct role in identifying the best leads for our targets with unprecedented speed and accuracy, assisting with our efforts to address the undruggable genome with the goal of delivering transformational impact for patients with inflammatory diseases and cancer in record time," Gary D. Glick, Odyssey Therapeutics Founder and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.